A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease

Summary

This is a Phase 2, multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks, a 4 week randomized double-blind, dose-titration treatment period, followed by a 1 week safety follow-up period after the last dose of study medication, and a scheduled follow-up safety telephone call one week later.

Timeline

Start

2019-12

Primary completion

2020-09

Completion

2020-12

Drugs

Indications